<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972439</url>
  </required_header>
  <id_info>
    <org_study_id>HS-07-00269</org_study_id>
    <nct_id>NCT00972439</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive (OC) Progestin Dose and Breast Proliferation</brief_title>
  <official_title>Evaluating the Effect of Oral Contraceptive Progestin Dose on Breast Epithelial Cell Proliferation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to gain a better understanding of the changes that may
      occur in the breast when a woman uses an oral contraceptive (birth control pill). Some
      research indicates that women who use birth control pills with lower amounts of progestin (a
      hormone in the birth control pill) may have lower breast cell growth than women who use birth
      control pills with a higher amount of progestin; this research will examine that in detail.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breast Cell Proliferation Levels Between the Two Oral Contraceptive Dose Groups</measure>
    <time_frame>32 weeks</time_frame>
    <description>Percent of cells expressing staining for Ki67 will be examined in breast epithelial cells</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Oral Contraceptive</condition>
  <arm_group>
    <arm_group_label>Ortho-Novum® 1/35</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovcon Fe®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovcon Fe® is an oral contraceptive that contains less progestin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive: Ortho-Novum® 1/35</intervention_name>
    <arm_group_label>Ortho-Novum® 1/35</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive: Ovcon Fe®</intervention_name>
    <arm_group_label>Ovcon Fe®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-34.

          2. Premenopausal.

          3. Currently taking or want to start oral contraceptives for contraception

          4. Non-smoker.

          5. Competent to give informed consent (as judged by the investigator).

          6. Provided written informed consent.

          7. Willingness to refrain from smoking and consumption of grapefruit or grapefruit juice
             during the study (grapefruit interferes with metabolism of exogenously administered
             OCs).

        Exclusion Criteria:1.

          1. Abnormal breast examination.

          2. History or current therapeutic or prophylactic use of anticoagulants.

          3. Known bleeding disorder or history of unexplained bleeding or bruising.

          4. History of breast cancer or previous diagnostic breast biopsy.

          5. Known allergy to local anesthetic.

          6. Currently pregnant or pregnant within the previous 6 months.

          7. Having any standard contra-indication to being prescribed OCs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DeShawn Taylor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2009</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>January 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2018</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Contraceptives</keyword>
  <keyword>Breast Tissue</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Progestins</mesh_term>
    <mesh_term>Mestranol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates: April 2008 - October 2008 Ob/gyn clinics</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ortho-Novum® 1/35</title>
          <description>Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.</description>
        </group>
        <group group_id="P2">
          <title>Ovcon Fe®</title>
          <description>Ovcon Fe® is an oral contraceptive that contains less progestin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ortho-Novum® 1/35</title>
          <description>Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.</description>
        </group>
        <group group_id="B2">
          <title>Ovcon Fe®</title>
          <description>Ovcon Fe® is an oral contraceptive that contains less progestin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="4.4"/>
                    <measurement group_id="B2" value="28.1" spread="4.8"/>
                    <measurement group_id="B3" value="26.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Breast Cell Proliferation Levels Between the Two Oral Contraceptive Dose Groups</title>
        <description>Percent of cells expressing staining for Ki67 will be examined in breast epithelial cells</description>
        <time_frame>32 weeks</time_frame>
        <population>Five of the breast biopsy specimens contained insufficient TDLU epithelial tissue for analysis and one of the remaining women was diagnosed with a follicular cyst on the day of the biopsy, leaving 27 evaluable women.</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho-Novum® 1/35</title>
            <description>Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.</description>
          </group>
          <group group_id="O2">
            <title>Ovcon Fe®</title>
            <description>Ovcon Fe® is an oral contraceptive that contains less progestin.</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Cell Proliferation Levels Between the Two Oral Contraceptive Dose Groups</title>
          <description>Percent of cells expressing staining for Ki67 will be examined in breast epithelial cells</description>
          <population>Five of the breast biopsy specimens contained insufficient TDLU epithelial tissue for analysis and one of the remaining women was diagnosed with a follicular cyst on the day of the biopsy, leaving 27 evaluable women.</population>
          <units>Percent of cells staining for Ki67</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="3.8" upper_limit="14.6"/>
                    <measurement group_id="O2" value="12.4" lower_limit="6.3" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected beginning day 1 of study and continued throughout the study until 30 days after the last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ortho-Novum® 1/35</title>
          <description>Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.</description>
        </group>
        <group group_id="E2">
          <title>Ovcon Fe®</title>
          <description>Ovcon Fe® is an oral contraceptive that contains less progestin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Celeste Pearce, Ph.D.</name_or_title>
      <organization>USC/Norris Comprehensive Cancer Center</organization>
      <phone>323 865 0437</phone>
      <email>cpearce@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

